Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.

Calogero Camma', Vito Di Marco, Antonio Craxi, Giuseppe Cabibbo, Massimo Colombo, Marco Biolato, Simona Racco, Alberto Borghi, Erica Villa, Sara Vavassori, Luigi Bolondi, Antonio Grieco, Maurizio Pompili, Antonio Grieco, Antonio Craxì, Alessandro Granito, Antonio Grieco, Alessandro Granito, Antonio Grieco, Giovambattista PinzelloAngelo Sangiovanni, Massimo Iavarone, Aldo Airoldi, Claudio Zavaglia, Fabio Piscaglia, Nicola De Maria, Vito Di Marco, Barbara Lei, Antonio Craxì, Raffaella Romeo

Risultato della ricerca: Articlepeer review

259 Citazioni (Scopus)

Abstract

A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC). Because the study was prematurely interrupted due to survival benefits in the sorafenib arm, we conducted an observational study to adequately assess risks and benefits of this regimen in field practice. Starting in 2008, all clinically compensated patients with advanced HCC and those with an intermediate HCC who were unfit or failed to respond to ablative therapies were consecutively evaluated in six liver centers in Italy, for tolerability as well as radiologic and survival response to 800-mg/d sorafenib therapy. Treatment was down-dosed or interrupted according to drug label. Two hundred ninety-six patients (88% Child-Pugh A, 75% Barcelona Clinic Liver Cancer [BCLC]-C, and 25% BCLC-B) received sorafenib for 3.8 months (95% CI 3.3-4.4). Two hundred sixty-nine (91%) patients experienced at least one adverse event (AE), whereas 161 (54%) had to reduce dosing. Treatment was interrupted in 103 (44%) for disease progression, in 95 (40%) for an AE, and in 38 (16%) for liver deterioration. The median survival was 10.5 months in the overall cohort, 8.4 months in BCLC-C versus 20.6 months in BCLC-B patients (P < 0.0001), and 21.6 months in the 77 patients treated for >70% of the time with a half dose versus 9.6 months in the 219 patients treated for >70% of the time with a full dose. At month 2 of treatment, the overall radiologic response was 8%. Eastern Cooperative Oncology Group performance status, macrovascular invasion, extrahepatic spread of the tumor, radiologic response at month 2, and sorafenib dosing were independent predictors of shortened survival. Conclusion: Overall, safety, effectiveness, and generalizability of sorafenib therapy in HCC was validated in field practice. The effectiveness of half-dosed sorafenib may have implications for tailored therapy.
Lingua originaleEnglish
Numero di pagine9
RivistaHEPATOLOGY
Volume54
Stato di pubblicazionePublished - 2011

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2721???

Fingerprint

Entra nei temi di ricerca di 'Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.'. Insieme formano una fingerprint unica.

Cita questo